Conjugate Or Complex Patents (Class 424/193.1)
-
Patent number: 8895257Abstract: Chimera proteins including: (i) at least one sequence of a VlsE protein of a Borrelia species selected from B. garinii, B. burgdorferi sensu stricto and B. afzelii, and (ii) at least one sequence including sequences of the IR6 domain of B. burgdorferi sensu stricto, B. afzelii and B. garinii. Also, a method and a kit for the in vitro diagnosis of Lyme borreliosis using said proteins.Type: GrantFiled: August 27, 2010Date of Patent: November 25, 2014Assignee: BiomerieuxInventors: Lionel Levet, Odile Mejan-Letourneur
-
Patent number: 8895020Abstract: Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a ?2-microglobulin sequence and a full-length MHC class I heavy chain sequence, joined by linker sequences. Further described are nucleic acids encoding single chain trimers. Methods for expansion of antigen-specific T cell populations using single chain trimer molecules are also disclosed. In some configurations, these methods comprise co-culturing, in a first stage, CD8+ T cells from a donor with antigen presenting cells comprising an MHC antigen peptide, and co-culturing, in a second stage, the CD8+ T cells with cells comprising an SCT which has an MHC antigen peptide sequence identical to the sequence of the antigen peptide in the first stage. The methods can provide 10,000-100,000 fold expansion of antigen-specific CD8+ T cells within about 28 days after establishing culture, and can yield over 1 billion antigen-specific CD8+ T cells expanded from an individual donor.Type: GrantFiled: April 4, 2006Date of Patent: November 25, 2014Assignee: Washington UniversityInventors: Ted Hansen, Yik Yeung Lawrence Yu
-
Patent number: 8895024Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.Type: GrantFiled: January 22, 2009Date of Patent: November 25, 2014Assignee: Wyeth LLCInventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
-
Patent number: 8895018Abstract: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II ?1 domain and the second domain is an MHC class II ?1 domain; or wherein the first domain is an MHC class I ?1 domain and the second domain is an MHC class I ?2 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen of the central or peripheral nervous system.Type: GrantFiled: June 21, 2013Date of Patent: November 25, 2014Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veteran AffairsInventors: Arthur A. Vandenbark, Gregory G. Burrows
-
Publication number: 20140341909Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: ApplicationFiled: June 27, 2014Publication date: November 20, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventor: Vince Pozsgay
-
Patent number: 8889143Abstract: Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK (SEQ ID NO: 2) residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.Type: GrantFiled: December 10, 2009Date of Patent: November 18, 2014Assignee: Antigen Express, Inc.Inventors: Robert Humphreys, Minzhen Xu
-
Patent number: 8889142Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.Type: GrantFiled: October 11, 2005Date of Patent: November 18, 2014Assignee: Statens Serum InstitutInventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
-
Patent number: 8883160Abstract: The prediction of protein function as well as the reconstruction of evolutionary genesis employing sequence comparison at large is still the most powerful tool in sequence analysis. Due to the exponential growth of the number of known protein sequences and the subsequent quadratic growth of the similarity matrix, the computation of the Similarity Matrix of Proteins (SIMAP) becomes a computational intensive task. The SIMAP database provides a comprehensive and up-to-date pre-calculation of the protein sequence similarity matrix, sequence-based features and sequence clusters. As of September 2009, SIMAP covers 48 million proteins and more than 23 million non-redundant sequences. Novel features of SIMAP include the expansion of the sequence space by including databases such as ENSEMBL as well as the integration of metagenomes based on their consistent processing and annotation.Type: GrantFiled: February 28, 2011Date of Patent: November 11, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8883165Abstract: A modified peptide derived from matrix protein 2 (hereinafter also referred to as “M2”), one of surface layer proteins of influenza virus, and a method for utilization of the modified peptide are provided. A peptide (hereinafter also referred to as “M2eC peptide”) that is made up by inserting cysteine residue(s) into a peptide (hereinafter also referred to as “M2e”) consisting of 23 amino acid residues of from positions No. 2 to No.Type: GrantFiled: August 23, 2010Date of Patent: November 11, 2014Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Kazuyoshi Kaminaka, Chikateru Nozaki, Junichi Matsuda, Kiyoto Nishiyama
-
Publication number: 20140328866Abstract: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.Type: ApplicationFiled: May 19, 2014Publication date: November 6, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventors: Geoffry L. Curran, Gobinda Sarkar, Joseph F. Poduslo, Robert B. Jenkins, Val J. Lowe, Erik W. Mahlum
-
Publication number: 20140328923Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicant: Selecta Biosciences, Inc.Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
-
Publication number: 20140328922Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.Type: ApplicationFiled: May 2, 2014Publication date: November 6, 2014Applicant: Selecta Biosciences, Inc.Inventor: Roberto A. Maldonado
-
Patent number: 8877207Abstract: Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof.Type: GrantFiled: July 18, 2011Date of Patent: November 4, 2014Assignees: University of Central Florida Research Foundation, Inc., University of l'AquilaInventors: Annamaria Cimini, Barbara D'Angelo, Soumen Das, Sudipta Seal
-
Patent number: 8877206Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.Type: GrantFiled: March 17, 2008Date of Patent: November 4, 2014Assignee: PDS Biotechnology CorporationInventors: Weihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang
-
Patent number: 8877204Abstract: The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods for the treatment and prevention of cancer and infectious disease. The invention also relates to methods for treating and preventing cancer and infectious disease using such complexes comprising, isolated from the serum of a mammal. The invention also encompasses methods for production of alpha (2) macroglobulin complexes.Type: GrantFiled: February 20, 2004Date of Patent: November 4, 2014Assignee: University of Connecticut Health CenterInventors: Pramod K. Srivastava, Robert J. Binder
-
Publication number: 20140322344Abstract: A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent.Type: ApplicationFiled: August 30, 2012Publication date: October 30, 2014Applicants: National University Corporation Tokyo Medical and Dental University, MIE UniversityInventors: Hiroshi Shiku, Naozumi Harada, Daisuke Muraoka, Kazunari Akiyoshi
-
Patent number: 8871216Abstract: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKK?/? and I?B?, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.Type: GrantFiled: November 5, 2012Date of Patent: October 28, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8871213Abstract: The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.Type: GrantFiled: August 28, 2009Date of Patent: October 28, 2014Assignee: Oral Health Australia Pty LtdInventors: Eric Charles Reynolds, Neil Martin O'Brien Simpson, Keith J Cross, Nada Slakeski
-
Publication number: 20140314804Abstract: The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. In another aspect, compositions that generally include an antigen component, a soluble beta-glucan component, and a TLR agonist component and a method that generally includes administering to a subject a composition that comprises a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen, are described.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Keith B. Gorden, Nandita Bose, Anissa S.H. Chan, William J. Grossman
-
Patent number: 8865176Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: GrantFiled: July 16, 2012Date of Patent: October 21, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 8865127Abstract: Provided herein is an antibody- or antibody fragment-targeted cationic immunoliposome complex prepared by a method comprising the steps of (a) preparing an antibody or antibody fragment; (b) mixing the antibody or antibody fragment with a cationic liposome and to form a cationic immunoliposome wherein the antibody or antibody fragment is complexed with the cationic liposome, but is not chemically conjugated to the cationic liposome and wherein said antibody or antibody fragment does not comprise a lipid tag; and (c) mixing the cationic immunoliposome with a therapeutic or diagnostic agent to form the antibody- or antibody fragment-targeted cationic immunoliposome.Type: GrantFiled: June 22, 2010Date of Patent: October 21, 2014Assignee: Georgetown UniversityInventors: Esther H. Chang, Kathleen F. Pirollo
-
Publication number: 20140308341Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).Type: ApplicationFiled: June 30, 2014Publication date: October 16, 2014Inventors: Gary FUJII, Francis C. SZOKA, JR., Douglas S. WATSON
-
Patent number: 8858955Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: GrantFiled: January 2, 2008Date of Patent: October 14, 2014Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Publication number: 20140302085Abstract: The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages.Type: ApplicationFiled: July 28, 2012Publication date: October 9, 2014Applicant: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICOInventors: Edda Lydia Sciutto Conde, Gladis del Carmen Fragoso Gonzalez, René Alvaro Segura Velázquez, Jacquelynne Brenda Cervantes Torres, Karen Manucharyan, Abel Blanca Cabrera, Rutilia Marisela Hernandez Gonzalez
-
Patent number: 8852603Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: GrantFiled: January 6, 2012Date of Patent: October 7, 2014Assignee: Syntaxin LimitedInventors: Keith Alan Foster, John Andrew Chaddock, Conrad Padraig Quinn, John Robert Purkiss
-
Patent number: 8852605Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: April 3, 2007Date of Patent: October 7, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20140294930Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.Type: ApplicationFiled: August 3, 2012Publication date: October 2, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Victor Nizet, Nina van Sorge
-
Patent number: 8846049Abstract: The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: GrantFiled: April 27, 2012Date of Patent: September 30, 2014Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Patent number: 8841416Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: GrantFiled: August 3, 2011Date of Patent: September 23, 2014Assignee: University of WashingtonInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
-
Patent number: 8834887Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.Type: GrantFiled: September 25, 2008Date of Patent: September 16, 2014Assignees: National Cerebral and Cardiovascular Center, Kowa Co., Ltd.Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
-
Patent number: 8834889Abstract: An antigen presenting composition comprising a plurality of 2-component MHC class I complexes and a carrier is described. A method for activating a group of antigen-specific CD8+ T cells comprising incubation of a group of naïve CD8+ T cells with the antigen presenting composition is also presented. A method for inducing the proliferation of a group of antigen-specific CD8+ T cells comprising incubation of a group of naïve CD8+ T cells with the antigen presenting composition is further described.Type: GrantFiled: August 29, 2011Date of Patent: September 16, 2014Assignee: National Tsing Hua UniversityInventor: Chien-Chung Chang
-
Patent number: 8828402Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.Type: GrantFiled: January 15, 2014Date of Patent: September 9, 2014Assignee: OmniGen Research, LLCInventors: Neil E. Forsberg, Steven B. Puntenney
-
Patent number: 8821881Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, blockpolymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A. CpG variants, CT and LT or fractions thereof.Type: GrantFiled: July 7, 2004Date of Patent: September 2, 2014Assignee: Novavax ABInventors: Bror Morein, Karin Lovgren Bengtsson, Jill Ekstrom, Katarina Ranlund, Kefei Hu
-
Patent number: 8821884Abstract: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g., a human patient with sepsis, e.g., gram negative septic shock. In one aspect, the invention is directed to chimeric proteins comprising the MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. In one aspect, the invention is directed to chimeric proteins comprising fragments or altered form of MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. The invention also provides pharmaceutical compositions comprising the chimeric polypeptides of the invention, and methods of making and using them, including methods for ameliorating or preventing sepsis.Type: GrantFiled: July 27, 2005Date of Patent: September 2, 2014Assignee: The Regents of the University of CaliforniaInventors: Theo N. Kirkland, III, Sunganya Viriyakosol
-
Patent number: 8821895Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.Type: GrantFiled: October 24, 2012Date of Patent: September 2, 2014Assignee: ID Biomedical Corporation of QuebecInventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
-
Publication number: 20140242173Abstract: This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Selecta Biosciences, Inc.Inventors: Charles Zepp, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Lloyd Johnston, Grayson B. Lipford
-
Patent number: 8815249Abstract: Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope, or said encoded protein or peptide. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide, or said encoded protein or peptide.Type: GrantFiled: July 26, 2010Date of Patent: August 26, 2014Assignee: Antigen Express, Inc.Inventors: Robert Humphreys, Minzhen Xu
-
Patent number: 8815250Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.Type: GrantFiled: March 11, 2013Date of Patent: August 26, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
-
Publication number: 20140234365Abstract: The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Applicant: ALERE SAN DIEGO, INC.Inventor: Mariusz Banaszczyk
-
Patent number: 8808707Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.Type: GrantFiled: April 26, 2007Date of Patent: August 19, 2014Assignee: Wyeth LLCInventors: George Rainer Siber, Peter R. Paradiso, Jill G. Hackell, Stephen Paul Lockhart, William P. Hausdorff
-
Patent number: 8808708Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.Type: GrantFiled: April 4, 2012Date of Patent: August 19, 2014Assignee: Wyeth LLCInventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
-
Patent number: 8808703Abstract: The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.Type: GrantFiled: March 23, 2011Date of Patent: August 19, 2014Inventors: Tom Yao-Hsiang Wu, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
-
Publication number: 20140227316Abstract: Compositions and methods are provided, comprising at least one beta-lactam compound selected from the group consisting of cefuroxime, a penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid (6-APA) and tazobactam, for enhancing T cell mediated immune responses in a subject, such as anti-tumor and anti-viral immune responses.Type: ApplicationFiled: September 20, 2012Publication date: August 14, 2014Applicant: STEM CELL MEDICINE LTD.Inventors: Irun R. Cohen, Felix Mor
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140220083Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.Type: ApplicationFiled: July 6, 2012Publication date: August 7, 2014Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
-
Patent number: 8795680Abstract: Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier.Type: GrantFiled: July 18, 2007Date of Patent: August 5, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, National Research Council of CanadaInventors: Joanna Kubler-Kielb, Vince Pozsgay, Teresa Lagergard, Gil Ben-Menachem, Rachel Schneerson, Evguenii Vinogradov, Ariel Ginzberg
-
Patent number: 8796423Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.Type: GrantFiled: April 18, 2008Date of Patent: August 5, 2014Assignee: Eli Lilly and CompanyInventors: Limin Li, Michael Kinch, Michael Goldbiatt
-
Publication number: 20140212446Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.Type: ApplicationFiled: April 8, 2014Publication date: July 31, 2014Applicant: The Trustees of The University of PennsylvaniaInventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
-
Patent number: 8790654Abstract: The invention provides compositions and kits comprising: (a) a saccharide antigen conjugated to a carrier; and (b) an alpha-glycosylceramide adjuvant. The invention further provides uses of the compositions. It has been found that suppression of anti-saccharide immune responses by alpha-glycosylceramides can be reversed by conjugating the saccharide to a carrier.Type: GrantFiled: September 7, 2005Date of Patent: July 29, 2014Assignee: Novartis AGInventor: Grazia Galli
-
Patent number: 8790665Abstract: There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of mixtures of peptides as a group, rather than for individual peptides with a defined amino acid sequence, are complicated by the heterogeneity of the peptides to be detected. This application provides improved methods of detecting and assessing random sequence polymer (RSP) compositions, methods for the detection and quantitation of RSP compositions, means to determine and enrich a subset of peptides in an RSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering RSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation.Type: GrantFiled: November 17, 2010Date of Patent: July 29, 2014Assignee: Ares Trading SAInventors: Eric H. Zanelli, Jeff Krieger, Joe Connolly, Kathryn H. Collins